EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetic and Bioavailability Analysis of Etomidate, Metomidate, and Propoxate in Mice Using UPLC–MS/MS

Jianshe Ma, Siyu Zhuo, Siyuan Chen, Xicheng Dong, Lufeng Hu iD, Xianqin Wang iD

Biomedical Chromatography · 2025

DOI: 10.1002/bmc.70242 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Jianshe Ma und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Etomidate, Imidazoles, Liquid Chromatography-Mass Spectrometry, Anesthetics, Intravenous. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Several studies have reported detection methods for etomidate and its analogues, metomidate and propoxate, but data on their pharmacokinetics and bioavailability are limited. This study develops a UPLC–MS/MS method to simultaneously detect these compounds and evaluates their pharmacokinetics and bioavailability in mice. Plasma samples were processed using methanol‐induced protein precipitation. The separation was conducted on a UPLC BEH C18 column with an acetonitrile‐water (containing 0.1% formic acid) as mobile phase at a flow rate of 0.4 mL/min, achieving elution within 4 min. Quantitative analysis was performed using MRM mode coupled with ESI in positive ion mode. In this study, mice received etomidate, metomidate, and propoxate via intravenous (1 mg/kg) and oral (10 mg/kg) routes, and the pharmacokinetics were evaluated. The calibration curves demonstrated excellent linearity within the ranges of 0.5–1000 ng/mL for etomidate, 0.504–1080 ng/mL for metomidate, and 0.77–1540 ng/mL for propoxate in mouse plasma, with correlation coefficients ( r values) exceeding 0.998. The developed UPLC‐MS/MS method was successfully utilized to analyze the pharmacokinetics of etomidate, metomidate, and propoxate. The absolute bioavailability of etomidate, metomidate, and propoxate was determined to be 14.0%, 21.3%, and 15.3%, respectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EtomidateImidazolesLiquid Chromatography-Mass SpectrometryAnesthetics, IntravenousBiological AvailabilityAnimalsMiceMaleMice, Inbred ICR

Stichwörter der Autor:innen

UPLC‐MS/MSetomidatemetomidatepharmacokineticspropoxate

Substanzen

EtomidatemetomidatepropoxateImidazolesAnesthetics, Intravenous

Autor:innen und Institutionen

  • School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China.
  • Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
  • Department of Neurosurgery, Wenzhou Municipal Key Laboratory of Neurodevelopmental Pathology and Physiology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.

ORCID-Profile: Lufeng Hu, Xianqin Wang

Zitieren

APA

Ma, J., Zhuo, S., Chen, S., Dong, X., Hu, L., & Wang, X. (2025). Pharmacokinetic and Bioavailability Analysis of Etomidate, Metomidate, and Propoxate in Mice Using UPLC–MS/MS. Biomedical Chromatography. https://doi.org/10.1002/bmc.70242

Vancouver

Ma J, Zhuo S, Chen S, Dong X, Hu L, Wang X. Pharmacokinetic and Bioavailability Analysis of Etomidate, Metomidate, and Propoxate in Mice Using UPLC–MS/MS. Biomedical Chromatography. 2025. doi:10.1002/bmc.70242

BibTeX
@article{Ma2025,
  author = {Ma, Jianshe and Zhuo, Siyu and Chen, Siyuan and Dong, Xicheng and Hu, Lufeng and Wang, Xianqin},
  title = {Pharmacokinetic and Bioavailability Analysis of Etomidate, Metomidate, and Propoxate in Mice Using UPLC–MS/MS},
  journal = {Biomedical Chromatography},
  year = {2025},
  doi = {10.1002/bmc.70242}
}
Kostenlos starten →